Reply: Perspectives on high-attenuation mucus, CT and MRI in allergic bronchopulmonary aspergillosis
- PMID: 40180363
- DOI: 10.1183/13993003.00196-2025
Reply: Perspectives on high-attenuation mucus, CT and MRI in allergic bronchopulmonary aspergillosis
Conflict of interest statement
Conflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company, and share options in TFF Pharma; he acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Biosergen, TFF Pharmaceuticals, Rostra Therapeutics, Mucpharma PTY and Lifemine Therapeutics; in the past 3 years, he has been paid for talks on behalf of Mundipharma, BioRad, Basilea, Gilead, Avir and Pfizer, and has been involved in multiple guideline groups, primarily focused on diagnostics and aspergillosis. The remaining authors have no potential conflicts of interest to disclose.
Comment on
-
Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.Eur Respir J. 2024 Apr 4;63(4):2400061. doi: 10.1183/13993003.00061-2024. Print 2024 Apr. Eur Respir J. 2024. PMID: 38423624 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources